Inflammatory arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, ankylosing spondylitis, reactive arthritis, Sjogren's syndrome and gout/pseudogout)
Joint aspiration and injection
If your insurance is not listed, please call our office if you have questions regarding your insurance coverage. If you have out-of-network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.
Assistant Attending Physician, Hospital for Special Surgery
Assistant Professor of Medicine, Weill Cornell Medical College
American College of Rheumatology, Member
American Board of Internal Medicine, Internal Medicine, 2019
American Board of Internal Medicine, Rheumatology, 2021
Medical: University of California, San Francisco, 2016
Internship: NewYork-Presbyterian - Weill Cornell Medical Center, 2017
Residency: NewYork-Presbyterian - Weill Cornell Medical Center, 2018
Fellowship: Hospital for Special Surgery, 2022
Dr. Smith conducts basic science and translational research in inflammatory arthritis with a focus on rheumatoid arthritis. She studies how cells that make up the healthy joint lining change with rheumatoid arthritis in order to identify novel therapeutic targets.
HSS has a long history of supporting appropriate relationships with industry because they advance HSS's mission to provide the highest quality patient care, improve patient mobility, and enhance the quality of life for all, and to advance the science of orthopedic surgery, rheumatology, and their related disciplines through research and education.
As of May 31, 2023, Dr. Smith reported no relationships with the healthcare industry.
HSS and its physicians make this information available to patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest and Commitment Policy prohibits physicians from collecting royalties on products they develop that are used on patients at HSS.